
Pharma Pulse 4/3/25: Understanding Copay Accumulators, Maximizers, and AFPs, How Pharmacies Can Better Support Employee Mental Health & more
The latest news for pharma industry insiders.
In the first part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Kimberly Westrich, chief strategy officer at the National Pharmaceutical Council, lays out the basics surrounding accumulators, maximizers, and AFPs.
Reducing stigma, improving mental health benefits, and addressing workload concerns all need to happen simultaneously.
Roche Holding AG said a high-dose version of Ocrevus, its multiple sclerosis drug, failed to outperform the original in a large study, potentially reducing the drugmaker’s ability to fend off cheaper copies.
The "Personalized Cancer Vaccine Market Opportunity & Clinical Trials Outlook 2025" report has been added to ResearchAndMarkets.com's offering.
Personalized cancer vaccines are emerging as a transformative force in next generation cancer treatment methodology, with emergent commercial potential fueled by advancements in biotechnology and an increasing demand for targeted therapies. These vaccines represent a tailored approach to cancer treatment, utilizing a patient's unique genetic makeup to craft vaccines that specifically target and eliminate cancer cells. The success of this approach is gaining traction, and the market for personalized cancer vaccines is expected to grow significantly by 2030. Companies like BioNTech, Moderna, and smaller players such as myNEO Therapeutics are at the forefront, using their expertise in mRNA technology, which was initially honed during the COVID-19 pandemic.
Have news you want us to share in Pharma Pulse? Reach out to Editor
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.